Assenagon Asset Management S.A. Has $38.13 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Assenagon Asset Management S.A. lessened its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 18.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,067,361 shares of the company’s stock after selling 694,378 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Amneal Pharmaceuticals were worth $38,127,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $26,000. Federated Hermes Inc. grew its holdings in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares during the period. Spire Wealth Management increased its holdings in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares in the last quarter. Transamerica Financial Advisors LLC increased its stake in Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares in the last quarter. Finally, Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 17.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMRX. Truist Financial lifted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. UBS Group began coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 21st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.80.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $17.23 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $17.86. The company has a 50 day simple moving average of $13.82 and a 200 day simple moving average of $13.40. The firm has a market cap of $5.50 billion, a PE ratio of 45.34 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. As a group, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.